A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer Clinical Trial

— FRESCO-2  

Official title:

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04322539
• Other study ID #: 2019-013-GLOB1
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: August 12, 2020
• Est. completion date: March 2024

Study information

• Verified date: September 2023
• Source: Hutchmed
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC.

Description:

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib in combination with BSC versus placebo in combination with BSC in metastatic colorectal cancer participants who have progressed on, or were intolerant to, chemotherapy, anti-VEGF and anti-EGFR biologics, and TAS-102 or regorafenib. Participants with MSI-H/MMR deficient tumors must have also received an immune checkpoint inhibitor if approved and available and if deemed appropriate. Subjects with BRAF-mutant tumors must have been treated with a BRAF inhibitor if approved and available and if deemed appropriate.

Metastatic colorectal cancer cannot be cured by surgery. Therefore, treatment principals are primarily aimed at controlling disease progression and prolonging survival. Standard first- and second-line therapy includes cytotoxic drugs such as 5-fluorouracil, oxaliplatin, and irinotecan; anti-VEGF therapy; and, if RAS wild type, anti-EGFR therapy. After the first two lines of chemotherapy, standard third-line treatment is either TAS-102 or regorafenib. There are currently no effective treatments for patients who have progressed on standard, approved therapies, and treatment options include reuse of prior therapies, clinical trials or BSC. Consequently, there is an unmet medical need for additional safe and effective treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 691
• Est. completion date: March 2024
• Est. primary completion date: July 29, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provide written informed consent;

• Age =18 years;

• Histologically and/or cytologically documented metastatic colorectal adenocarcinoma. RAS, BRAF, and microsatellite instability microsatellite instability (MSI)/mismatch repair (MMR) status for each patient must be documented, according to country level guidelines;

• Participants must have progressed on or been intolerant to treatment with either trifluridine/tipiracil (TAS-102) or regorafenib. Participants are considered intolerant to TAS-102 or regorafenib if they have received at least 1 dose of either agents and were discontinued from therapy for reasons other than disease progression. Participants who have been treated with both TAS-102 and regorafenib are permitted. Participants must also have been previously treated with standard approved therapies: fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if RAS wild-type, an anti-EGFR therapy;

• Participants with microsatellite-high (MSI-H) or mismatch repair deficient (dMMR) tumors must have been treated with immune checkpoint inhibitors if approved and available in the participant's country unless the patient is ineligible for treatment with a checkpoint inhibitor;

• Participants who received oxaliplatin in the adjuvant setting and developed metastatic disease during or within 6 months of completing adjuvant therapy are considered eligible without receiving oxaliplatin in the metastatic setting. Participants who developed metastatic disease more than 6 months after completion of oxaliplatin-containing adjuvant treatment must be treated with oxaliplatin-based therapy in the metastatic setting to be eligible;

• Body weight =40kg;

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

• Have measurable disease according to RECIST Version 1.1, assessed locally. Tumors that were treated with radiotherapy are not measurable per RECIST Version 1.1, unless there has been documented progression of those lesions;

• Expected survival >12 weeks.

• For female participants of childbearing potential and male participants with partners of childbearing potential, agreement to use a highly effective form(s) of contraception, that results in a low failure rate (<1% per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire study period, and for 90 days after taking the last dose of study drug. Such methods include: oral hormonal contraception (combined estrogen/ progestogen, or progestogen-only) associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal ligation, vasectomized partner, or true sexual abstinence in line with the preferred and usual lifestyle of the participant. Highly effective contraception should always be combined with an additional barrier method (eg, diaphragm, with spermicide). The same criteria are applicable to male participants involved in this clinical trial if they have a partner of childbirth potential, and male participants must always use a condom.

• Participants with BRAF-mutant tumors must have been treated with a BRAF inhibitor if approved and available in the participant's home country unless the patient is ineligible for treatment with a BRAF inhibitor.

Exclusion Criteria:

• Absolute neutrophil count (ANC) <1.5×109/L, platelet count <100×109/L, or hemoglobin <9.0 g/dL. Blood transfusion within 1 week prior to enrollment for the purpose of increasing the likelihood of eligibility is not allowed;

• Serum total bilirubin >1.5 × the upper limit of normal (ULN). Participants with Gilbert syndrome, bilirubin <2 X ULN, and normal AST/ALT are eligible;

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 × ULN in participants without hepatic metastases; ALT or AST >5 × ULN in participants with hepatic metastases;

• Serum creatinine >1.5 × ULN or creatinine clearance <60 mL/min. Creatinine clearance can either be measured in a 24-hour urine collection or estimated by the Cockroft-Gault equation.

• Urine dipstick protein =2+ or 24-hour urine protein =1.0 g/24-h. Participants with greater than 2+ proteinuria by dipstick must undergo a 24-hour urine collection to assess urine protein level;

• Uncontrolled hypertension, defined as: systolic blood pressure =140 mm Hg and/or diastolic blood pressure =90 mm Hg despite optimal medical management. Participants were required to have blood pressure values below both limits. Repeated assessments were permitted;

• International Normalized Ratio (INR) >1.5 x ULN or activated partial thromboplastin time (aPTT) >1.5 × ULN, unless the patient is currently receiving or intended to receive anticoagulants for prophylactic purposes;

• History of, or active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, history of perforation or fistulas; or any other condition that could, in the investigator's judgment, result in gastrointestinal hemorrhage or perforation; within the 6 months prior to screening;

• History or presence of hemorrhage from any other site (eg, hemoptysis or hematemesis) within 2 months prior to screening;

• History of a thromboembolic event, including deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial embolism within 6 months prior to screening.

• Stroke and/or transient ischemic attack within 12 months prior to screening;

• Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction or coronary artery bypass surgery within 6 months prior to enrollment, severe or unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left ventricular ejection fraction (LVEF) <50% by echocardiogram;

• Mean corrected QT interval using the Fridericia method (QTcF) >480 msec or any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in a first-degree relative.

• Concomitant medications with a known risk of causing QT prolongation and/or Torsades de Pointes.

• Systemic anti-neoplastic therapies (except for those described in Exclusion 18) or any investigational therapy within 4 weeks prior to the first dose of study drug, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy and immunotherapy;

• Systemic small molecule targeted therapies (eg, tyrosine kinase inhibitors) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;

• Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of study drug;

• Brachytherapy (i.e., implantation of radioactive seeds) within 60 days prior to the first dose of study drug.

• Use of strong inducers or inhibitors of CYP3A4 within 2 weeks (or 5 half-lives, whichever is longer) before the first dose of study drug;

• Surgery or invasive procedure (i.e., a procedure that includes a biopsy; central venous catheter placement is allowed) within 60 days prior to the first dose of study drug or unhealed surgical incision;

• Any unresolved toxicities from a previous antitumor treatment greater than CTCAE v5.0 Grade 1 (except for alopecia or neurotoxicity grade=2);

• Known human immunodeficiency virus (HIV) infection;

• Known history of active viral hepatitis. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Participants with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load.

• Clinically uncontrolled active infection requiring IV antibiotics;

• Tumor invasion of a large vascular structure, eg, pulmonary artery, superior or inferior vena cava;

• Women who are pregnant or lactating;

• Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease for 14 days or longer; participants requiring steroids within 4 weeks prior to start of study treatment are excluded;

• Other malignancy, except for non-melanoma skin cancer, in situ cervical ca or bladder ca (Tis and T1) that have been adequately treated during the 5 years prior to screening;

• Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery (eg, gastric bypass) or a severe gastrointestinal disease, or any other condition that investigators believe may affect absorption of the investigational product;

• Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition (e.g., current alcohol or drug abuse) that investigators suspect may prohibit use of the investigational product, affect interpretation of study results, or put the patient at undue risk of harm based on the investigator's assessment;

• Known hypersensitivity to fruquintinib (or placebo) or any of its inactive ingredients including the azo dyes Tartrazine - FD&C Yellow 5 and Sunset yellow FCF - FD&C Yellow 6;

• Participants who have received prior fruquintinib;

• Live vaccine <28days before the first dose of study drug(s). Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colon Cancer
• Metastatic Colorectal Cancer

Intervention

Drug:
• Fruquintinib
Oral VEGFR inhibitor
• Placebo
Placebo capsule

Locations

Country	Name	City	State
Australia	Flinders Medical Centre	Adelaide	South Australia
Australia	The Queen Elizabeth Hospital	Adelaide	South Australia
Australia	Integrated Clinical Oncology Network Pty Ltd (Icon)	Brisbane	Queensland
Australia	Austin Hopistal Medical Oncology Unit	Melbourne	Victoria
Australia	Monash Health	Melbourne	Victoria
Australia	Western Health	Melbourne	Victoria
Austria	Ordensklinikum Linz Barmherzige Schwestern	Linz	AUT
Austria	Schwerpunktkrankenhaus Feldkirch	Rankweil	AUT
Austria	Klinikum Steyr	Steyr	AUT
Austria	Klinikum Wels-Grieskirchen GmbH	Wels	AUT
Austria	Wiener Gesundheitsverbund - Klinik Ottakring	Wien	AUT
Austria	Landesklinikum Wiener Neustadt	Wiener Neustadt	AUT
Belgium	Onze-Lieve-Vrouwziekenhuis OLV - Campus Aalst	Aalst	BEL
Belgium	UCL St-Luc	Brussels	BEL
Belgium	Grand Hopital de Charleroi	Charleroi	BEL
Belgium	UZ Antwerpen	Edegem	BEL
Belgium	Centres Hospitaliers Jolimont	Haine-Saint-Paul	BEL
Belgium	UZ Leuven	Leuven	BEL
Belgium	CHU de Lige - Domaine Universitaire du Sart Tilman	Liège	Wallonia
Belgium	Clinique CHC MontLegia	Liège	Wallonia
Belgium	AZ Delta Roeselare	Roeselare	BEL
Belgium	AZ Turnhout	Turnhout	BEL
Belgium	CHU Mont-Godinne	Yvoir	BEL
Czechia	Masaryk Memorial Cancer Institute, Hematoonkologie	Brno	Moravia
Czechia	Fakultni nemocnice Olomouc, Onkologicka klinika	Olomouc	Moravia
Czechia	Vseobecna Fakultni Nemocnice VFN, Onkologicka Klinika	Prague
Estonia	East Tallinn Central Hospital Centre of Oncology	Tallinn	Harju
Estonia	Sihtasutus Pohja-Eesti Regionaalhaigla (PERH) (North Estonia Medical Centre)	Tallinn	Harju
Estonia	Tartu University Hospital Clinic of Haematology and Oncology	Tartu
France	CHU Besancon	Besançon	Franche-Comte
France	Institut Bergonie	Bordeaux	FRA
France	Unicancer	Caen	FRA
France	Centre Georges-Francois Leclerc	Dijon	FRA
France	ICM-Val d'Aurelle	Montpellier	FRA
France	Hopital Pitie Salptriere	Paris	FRA
France	Hopital St Antoine	Paris	FRA
France	Saint-Louis Hospital	Paris	FRA
France	CHU Poitiers	Poitiers	FRA
France	Centre hospitalier Annecy Genevois	Pringy	FRA
France	Centre Hospitalier Universitaire CHU de Rennes - Hopital de Pontchaillou	Rennes	FRA
France	Institut de cancerologie Strasbourg-Europe	Strasbourg	FRA
France	Institut Gustave Roussy	Villejuif	Paris
Germany	Charite - Universitaetsmedizin Berlin	Berlin	DEU
Germany	HELIOS Klinikum Berlin-Buch Saarow	Berlin	DEU
Germany	Universitaetsklinik Dresden	Dresden	DEU
Germany	Universitaetsklinikum Erlangen	Erlangen	Bavaria
Germany	University Hospital Essen	Essen	DEU
Germany	Institut fr Klinisch Onkologische ForschungKrankenhaus Nordwest GmbH	Frankfurt Am Main	DEU
Germany	Asklepios Tumorzentrum Hamburg AK Altona	Hamburg	DEU
Germany	Haematologisch-Onkologische Praxis Hamburg Eppendorf	Hamburg	DEU
Germany	Universitaeres Krebszentrum Leipzig	Leipzig	DEU
Germany	RKH Kliniken	Ludwigsburg	DEU
Germany	Universitaetsmedizin Mannheim- III. Medizinische Klinik	Mannheim	DEU
Germany	Klinikum Neuperlach	Muenchen	DEU
Germany	Zentrum für Hämatologie und Onkologie MVZ GmbH	Porta Westfalica	DEU
Hungary	Del-Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet, Szent Laszlo Korhaz	Budapest	HUN
Hungary	Magyar Honvedseg Egeszsegugyi Kozpont	Budapest	HUN
Hungary	National Institute of Oncology	Budapest	HUN
Hungary	Debreceni Egyetem Klinikai Kozpont	Debrecen	HUN
Hungary	Bekes Megyei Kozponti Korhaz, Pandy Kalman Tagkorhaz, Megyei Onkologiai Kozpont	Gyula
Hungary	Somogy Megyei Kaposi Mor Oktato Korhaz, Klinikai Onkologiai Osztaly	Kaposvár	Somogy
Hungary	Bacs- Kiskun Megyei Korhaz	Kecskemét	HUN
Hungary	Szabolcs-Szatmar-Bereg megyei Korhazak es Egyetemi Oktatokorhaz	Nyiregyhaza	HUN
Hungary	Hetenyi G Korhaz, Onkologiai Kozpont	Szolnok	HUN
Hungary	Szent Borbala Korhaz	Tatabanya	HUN
Hungary	Zala Megyei Szent Rafael Korhaz, Onkologiai Osztaly, F epulet 3. em.	Zalaegerszeg	Zala
Italy	Fondazione Poliambulanza Hospital	Brescia	ITA
Italy	Policlinico San Martino di Genova	Genova	ITA
Italy	ASST Grande Ospedale Metropolitano Niguarda	Milano	ITA
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori	Milano	ITA
Italy	Istituto Nazionale Tumori IRCCS Fondazione G. Pascale	Naples	ITA
Italy	Istituto Oncologico Veneto Irccs	Padova	ITA
Italy	Azienda Ospedaliero Universitaria Pisana	Pisa	ITA
Italy	Azienda USL-IRCCS di Reggio Emilia	Reggio Emilia	ITA
Italy	Istituto Clinico Humanitas	Rozzano MI	Lombardy
Italy	AO Card G Panico	Tricase	ITA
Italy	Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est	Vicenza	ITA
Japan	National Cancer Center Hospital	Chuo-ku	Tokyo
Japan	Kyushu Cancer Center	Fukuoka-shi	Fukuoka
Japan	National Cancer Center Hospital East	Kashiwa-shi	Chiba
Japan	St. Marianna University School of Medicine Hospital	Kawasaki-shi	Kanagawa
Japan	Shikoku Cancer Center	Matsuyama City	Ehime
Japan	Aichi Cancer Center	Nagoya	Aichi
Japan	Kindai University Hospital	Osakasayama-shi	Osaka
Japan	Hokkaido University Hospital	Sapporo-shi	Hokkaido
Japan	Shizuoka Cancer Center	Shizuoka	Sunto-gun
Japan	Osaka University Hospital	Suita-shi	Osaka
Poland	Bialostockie Centrum Onkologii im. Marii Skodowskiej-Curie	Bialystok	Podlaskie
Poland	M Sklodowska Curie Memorial Cancer Center, Klinika Gastroenterologii Onkologicznej	Warszawa	Masovia
Spain	Hospital Universitari Vall dHebron	Barcelona	ESP
Spain	Hospital Universitario Reina Sofa	Córdoba	ESP
Spain	Hospital General Universitario de Elche	Elche	ESP
Spain	Hospital Clinico San Carlos	Madrid	ESP
Spain	Hospital General Universitario Gregorio Maranon HGUGM	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid	ESP
Spain	Hospital Universitario HM Sanchinarro	Madrid	ESP
Spain	Hospital Universitario La Paz	Madrid	ESP
Spain	Hospital Universitario Ramón y Cajal	Madrid	ESP
Spain	Hospital Universitario Puerta de Hierro	Majadahonda	ESP
Spain	Hospital Regional Universitario Carlos Haya	Malaga	ESP
Spain	Hospital Universitario Central de Asturias	Oviedo	ESP
Spain	Hospital Universitario Marques de Valdecilla	Santander	ESP
Spain	Hospital ClÃ-nico Universitario de Santiago-CHUS	Santiago De Compostela	ESP
Spain	Hospital Universitario Virgen del Rocio	Sevilla
Spain	Hospital Clinico Universitario de Valencia	Valencia
United Kingdom	Aberdeen Royal Infirmary	Aberdeen	GBR
United Kingdom	Sarah Cannon Research Institute UK	London	Middlesex
United Kingdom	The Royal Marsden Hospital	London	GBR
United States	XCancer / New Mexico Oncology & Hematology Consultants	Albuquerque	New Mexico
United States	University of Michigan Health System	Ann Arbor	Michigan
United States	Illinois Cancer Specialists	Arlington Heights	Illinois
United States	Emory Winship Cancer Institute	Atlanta	Georgia
United States	Rocky Mountain Cancer Center	Aurora	Colorado
United States	Texas Oncology - Austin	Austin	Texas
United States	Hematology Oncology Clinic	Baton Rouge	Louisiana
United States	Charleston Oncology	Charleston	South Carolina
United States	University of Chicago Medical Center	Chicago	Illinois
United States	Affiliated Oncologists	Chicago Ridge	Illinois
United States	Maryland Oncology Hematology, P.A.	Columbia	Maryland
United States	Texas Oncology Baylor Sammons	Dallas	Texas
United States	Barbara Ann Karmanos Cancer Institute	Detroit	Michigan
United States	Texas Oncology-El Paso	El Paso	Texas
United States	Providence Regional Cancer Partnership	Everett	Washington
United States	Sarah Cannon Research Institute-S-Ft. Myers (FCS South)	Fort Myers	Florida
United States	XCancer / Central Care Cancer Center	Garden City	Kansas
United States	XCancer / Pontchartrain Cancer Center	Hammond	Louisiana
United States	MD Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic Florida	Jacksonville	Florida
United States	Center for Pharmaceutical Research	Kansas City	Missouri
United States	Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada
United States	California Research Institute (CRI)	Los Angeles	California
United States	City of Hope Comprehensive Cancer Center	Los Angeles	California
United States	Norton Cancer Institute Audubon	Louisville	Kentucky
United States	University of Louisville - James Brown Cancer Center	Louisville	Kentucky
United States	Texas Oncology-McAllen	McAllen	Texas
United States	Mount Sinai Medical Center	Miami Beach	Florida
United States	Medical College of Wisconsin/ Froedtert Hospital	Milwaukee	Wisconsin
United States	Minnesota Oncology	Minneapolis	Minnesota
United States	Sarah Cannon Tennessee Oncology	Nashville	Tennessee
United States	Vanderbilt Ingram Cancer Center	Nashville	Tennessee
United States	Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey
United States	Virginia Oncology Associates	Norfolk	Virginia
United States	Cancer Care Centers of Brevard, Inc.	Palm Bay	Florida
United States	Mayo Clinic Arizona	Phoenix	Arizona
United States	Mayo Clinic Rochester	Rochester	Minnesota
United States	Sarah Cannon Research Institute-N-St Pete (FCS North)	Saint Petersburg	Florida
United States	Texas Oncology-San Antonio	San Antonio	Texas
United States	Sarah Cannon Research Institute-Pan-Tallahassee (FCS Panhandle)	Tallahassee	Florida
United States	Arizona Oncology Associates, PC-HOPE	Tucson	Arizona
United States	Texas Oncology-Tyler	Tyler	Texas
United States	Northwest Cancer Specialists, P.C.	Vancouver	Washington
United States	The George Washington University Medical Center	Washington	District of Columbia
United States	Sarah Cannon Research-E-WPB (Florida Cancer Specialists-FCS East)	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Hutchison Medipharma Limited

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Czechia,  Estonia,  France,  Germany,  Hungary,  Italy,  Japan,  Poland,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	OS was defined as the time (months) from date of randomization to death from any cause. OS was calculated as (date of death or last known alive - date of randomization + 1)/30.4375. Participants without report of death at the time of analysis will be censored at the date last known alive.	From date of randomization to death from any cause (up to 22 months)
Secondary	Progression Free Survival (PFS), as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1	PFS was defined as the time (months) from randomization until the first radiographic documentation of objective progression as assessed by investigator using RECIST v1.1, or death from any cause, whichever comes first. More specifically, PFS was determined using all data until the last evaluable visit prior to or on the date of: (i) radiographic disease progression (PD) per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy other than the study drugs, whichever was earlier. PD was defined as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; and the appearance of one or more new lesions.	From randomization until the first documentation of objective progression or death, whichever comes first (up to 22 months)
Secondary	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)	ORR was defined as the percentage of participants who achieved a best overall response of confirmed complete response (CR) or partial response (PR), per RECIST v1.1, as determined by the investigator. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<)10 millimeters (mm).	From randomization until the first documentation of best overall response (up to 22 months)
Secondary	Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)	DCR was defined as percentage of participants achieving a best overall response of confirmed CR, PR, or stable disease (SD) (for at least 7 weeks) per RECIST v1.1, as determined by the investigator. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.	From randomization until the first documentation of best overall response (up to 22 months)
Secondary	Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)	DOR was defined as the time (in months) from the first occurrence of PR or CR by RECIST Version 1.1, until the first date that progressive disease is documented by RECIST Version 1.1, or death, whichever comes first. Only those participants with confirmed responses of CR or PR were included in this analysis. DOR was calculated as (date of death or PD or last assessment - date of first occurrence of confirmed CR or PR + 1)/30.4375.	From first occurrence of PR or CR until the first documentation progression or death, whichever comes first (up to 22 months
Secondary	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs	An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE was considered a TEAE if the onset date was on or after the start of study treatment or if the onset date was missing, or if the AE had an onset date before the start of study treatment but worsened in severity after the study treatment until 37 days after the last dose of study treatment or a new treatment of anti-tumor therapy, whichever was earlier. After this period, treatment-related SAEs were also considered as TEAEs. AEs with an unknown/not reported onset date were also included.	From start of study drug administration up to 22 months
Secondary	Observed Plasma Concentrations of Fruquintinib and Metabolite M11	Plasma samples were collected from the participants at the defined time points. Plasma concentrations were measured using a validated, specific, and sensitive liquid chromatography tandem mass spectrometry method. M11 is the active metabolite for the study drug.	Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 (Day 21): Predose and 2 hours, Cycle 3 (Day 1): Pre-dose, Cycle 3 (Day 21): Pre-dose and 2 hours, Cycle 5, 7, 9, 11, 13, 15 and 17 (Day 1): Pre-dose (Each cycle = 28 days)
Secondary	Change From Baseline of Electrocardiogram (ECG) Results - QTcF Intervals Using Fridericia's Formula	QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 milliseconds (msec). QTc: QT interval corrected based on the patient's heart rate. QTcF: An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula. QTc = QT/?(RR) RR = Respiration rate.	Baseline, Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 and 3 (Day 21): Pre-dose (Each cycle = 28 days)
Secondary	Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula	QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 msec. QTc: QT interval corrected based on the patient's heart rate. QTcB: An electrocardiographic finding in which the QT interval corrected for heart rate using Bazzett's formula.	Baseline, Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 and 3 (Day 21): Pre-dose (Each cycle = 28 days)
Secondary	Correlation Between Fruquintinib Exposure-response With Efficacy (OS) and Safety (AEs) Endpoints	As pre-specified in Exposure-Response final analysis report, fruquintinib exposures response with efficacy and safety endpoints were performed along with data from other clinical studies and the integrated analyses were to be reported separately. Data is not reported for this outcome measure as its analysis is still ongoing and will be reported after study completion.	Up to 42 months
Secondary	Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score	EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale. EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all [best] to 4=Very Much [worst]) and 2 questions (7-point scale where 1=Very poor [worst] to 7= Excellent [best]). Raw scores are standardized and converted into scale scores ranging from 0 to 100. For global health status/QOL scale, higher scores represent better QOL. A negative change from baseline value indicates patient condition became worst. Change from baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life Scale scores was performed by visit (i.e., cycle), using a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach.	Baseline, Cycle 2, 3 and 4 (Each cycle=28 days)
Secondary	Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS) Score	The EQ-5D-5L is a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score. There were two components to the EQ-5D-5L: a five-item health state profile that assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score and a general VAS score for health status. EQ-5D VAS was used to record participant's rating for his/her current health-related quality of life state on a vertical VAS with scores ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state. The higher the score the better the health status. A negative change from baseline value represents patient condition became worse. Change from baseline in the EQ-5D-5L VAS scores was performed by visit (i.e. cycle), using a REML-based MMRM approach.	Baseline, Cycle 2, 3 and 4 (Each cycle=28 days)
Secondary	Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores	EQ-5D-5L consisted of 2 components: health state profile and optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problem, 2= slight problem, 3= moderate problem, 4= severe problem, and 5= extreme problem. The response levels collected from the EQ-5D-5L five dimensions as a health profile are converted into an EQ-5D-5L index (utility) scores to represent participants' utility value. The range of health utility index score is from -0.285 to 1, where higher value indicates perfect health and a negative value represents a state worse than dead. Change from baseline in EQ-5D-5L health utility index scores was performed by visit (i.e., cycle), using a REML-based MMRM approach.	Baseline, Cycle 2, 3 and 4 (Each cycle=28 days)
Secondary	Health Care Resource Utilization: Duration of Hospital Visits by Participants	Duration of hospital visit was calculated as = stop date - start date + 1. Mean and standard deviation data for duration of hospital visits (in days) by participants was reported in this outcome measure.	From start of study drug administration up to 22 months
Secondary	Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed	Number of participants with any concomitant medications prescribed were reported.	From start of study drug administration up to 22 months